东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002675 东诚药业

已收盘 07-26 15:00:00

{"stockData":{"symbol":"002675","market":"SZ","secType":"STK","nameCN":"东诚药业","latestPrice":12.02,"timestamp":1721977422000,"preClose":11.69,"halted":0,"volume":5421300,"delay":0,"floatShares":766000000,"shares":825000000,"eps":0.2716,"marketStatus":"已收盘","marketStatusCode":5,"change":0.33,"latestTime":"07-26 15:00:00","open":11.72,"high":12.04,"low":11.65,"amount":64214600,"amplitude":0.0334,"askPrice":12.03,"askSize":187,"bidPrice":12.02,"bidSize":47,"shortable":0,"etf":0,"ttmEps":0.2716,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"adr":0,"adjPreClose":11.69,"symbolType":"stock","openAndCloseTimeList":[[1721957400000,1721964600000],[1721970000000,1721977200000]],"highLimit":12.86,"lowLimit":10.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":824595705,"pbRate":1.93,"roa":"--","roe":"1.34%","epsLYR":0.2543,"committee":-0.392092,"marketValue":9912000000,"floatMarketCap":9204000000,"peRate":44.256258,"changeRate":0.0282,"turnoverRate":0.0071,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-07-29。"},"requestUrl":"/m/hq/s/002675/wiki","defaultTab":"wiki","newsList":[{"id":"2449262490","title":"东诚药业(002675.SZ)：锝[⁹⁹ᵐTc]替曲膦注射液获得上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2449262490","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449262490?lang=zh_cn&edition=full","pubTime":"2024-07-05 21:02","pubTimestamp":1720184545,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)发布公告，公司全资子公司南京江原安迪科正电子研究发展有限公司(简称“安迪科”)收到国家药品监督管理局核准签发的锝[⁹⁹ᵐTc]替曲膦注射液《药品注册证书》，锝[⁹⁹ᵐTc]替曲膦注射液通过药品上市许可申请，可生产销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2449684402","title":"东诚药业（002675）7月4日主力资金净买入531.94万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449684402","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449684402?lang=zh_cn&edition=full","pubTime":"2024-07-05 09:20","pubTimestamp":1720142437,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月4日收盘，东诚药业报收于11.65元，下跌5.28%，换手率2.37%，成交量18.17万手，成交额2.13亿元。近5日资金流向一览见下表：东诚药业融资融券信息显示，融资方面，当日融资买入1883.01万元，融资偿还2509.84万元，融资净偿还626.83万元。东诚药业主营业务：肝素钠原料药、硫酸软骨素的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500012760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2448143564","title":"7月4日东诚药业跌5.28%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448143564","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448143564?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:22","pubTimestamp":1720081364,"startTime":"0","endTime":"0","summary":"证券之星消息，7月4日东诚药业跌5.28%创60日新低，收盘报11.65元，换手率2.37%，成交量18.17万手，成交额2.13亿元。重仓东诚药业的公募基金请见下表：该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为16.69。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为银河医药混合A。银河医药混合A目前规模为5.02亿元，最新净值0.4443，较上一交易日下跌2.5%，近一年下跌26.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400030725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","002675","BK1515","BK0239","BK1574","BK1161"],"gpt_icon":0},{"id":"2448992074","title":"东诚药业最新公告：下属公司获得FDA药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448992074","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448992074?lang=zh_cn&edition=full","pubTime":"2024-07-02 08:32","pubTimestamp":1719880356,"startTime":"0","endTime":"0","summary":"东诚药业公告，6月28日，公司下属公司蓝纳成药业收到美国食品药品监督管理局（FDA）核准签发的关于177Lu-LNC1011注射液的药品临床试验批准通知书，将于近期开展I期临床试验。该药品拟用于治疗PSMA阳性表达的晚期前列腺癌患者。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200005209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239","BK1141","BK1583","03347","BK1576"],"gpt_icon":0},{"id":"2448927962","title":"东诚药业(002675.SZ)下属公司获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448927962","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448927962?lang=zh_cn&edition=full","pubTime":"2024-07-02 08:16","pubTimestamp":1719879371,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)发布公告，2024年6月28日，公司下属公司蓝纳成药业收到美国食品药品监督管理局(简称“FDA”)核准签发的关于177Lu-LNC1011注射液的药品临床试验批准通知书(简称“SMP”)，将于近期开展I期临床试验。公司在研产品177Lu-LNC1011注射液是一种靶向前列腺特异性膜抗原(简称“PSMA”)的放射性体内治疗药物，拟用于治疗PSMA阳性表达的晚期前列腺癌患者。截至目前，177Lu-LNC1011注射液相关项目累计已投入研发费用约1522.45万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","002675","BK1141","03347","BK0239","BK1576"],"gpt_icon":0},{"id":"2446807581","title":"东诚药业（002675）6月25日主力资金净买入103.83万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446807581","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446807581?lang=zh_cn&edition=full","pubTime":"2024-06-26 09:23","pubTimestamp":1719365022,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月25日收盘，东诚药业报收于12.22元，下跌2.86%，换手率0.97%，成交量7.44万手，成交额9173.16万元。近5日资金流向一览见下表：东诚药业融资融券信息显示，融资方面，当日融资买入814.52万元，融资偿还709.86万元，融资净买入104.66万元，连续3日净买入累计2777.94万元。东诚药业主营业务：肝素钠原料药、硫酸软骨素的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600013877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2445937510","title":"东诚药业（002675）6月21日主力资金净卖出239.80万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445937510","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445937510?lang=zh_cn&edition=full","pubTime":"2024-06-24 09:14","pubTimestamp":1719191657,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月21日收盘，东诚药业报收于12.84元，上涨2.56%，换手率1.14%，成交量8.72万手，成交额1.12亿元。近5日资金流向一览见下表：东诚药业融资融券信息显示，融资方面，当日融资买入1200.23万元，融资偿还1023.95万元，融资净买入176.28万元，连续3日净买入累计699.36万元。东诚药业主营业务：肝素钠原料药、硫酸软骨素的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400001870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2444960284","title":"东诚药业（002675）6月18日主力资金净卖出1303.99万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444960284","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444960284?lang=zh_cn&edition=full","pubTime":"2024-06-19 09:05","pubTimestamp":1718759108,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月18日收盘，东诚药业报收于13.01元，下跌1.36%，换手率1.42%，成交量10.89万手，成交额1.42亿元。近5日资金流向一览见下表：东诚药业融资融券信息显示，融资方面，当日融资买入1760.17万元，融资偿还2037.7万元，融资净偿还277.54万元。东诚药业主营业务：肝素钠原料药、硫酸软骨素的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900014413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2443930991","title":"东诚药业新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2443930991","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443930991?lang=zh_cn&edition=full","pubTime":"2024-06-15 13:24","pubTimestamp":1718429089,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日烟台东诚药业集团股份有限公司新提交1件商标注册申请。商标申请详情如下：今年以来烟台东诚药业集团股份有限公司新申请注册商标1件，截止目前公司共持有注册商标503件，另有13件商标尚在注册申请中。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061500013745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2443629638","title":"东诚药业(002675.SZ)2023年度权益分派：每10股派1.25元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443629638","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443629638?lang=zh_cn&edition=full","pubTime":"2024-06-14 19:57","pubTimestamp":1718366244,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)发布公告，公司2023年年度权益分派方案为：以公司现有总股本为基数，向全体股东每10股派1.25元人民币现金(含税)，本次权益分派股权登记日为：2024年6月21日，除权除息日为：2024年6月24日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1135708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2443504862","title":"东诚药业最新公告：合肥核药生产中心投入运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2443504862","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443504862?lang=zh_cn&edition=full","pubTime":"2024-06-13 19:20","pubTimestamp":1718277637,"startTime":"0","endTime":"0","summary":"东诚药业公告，公司近日收到全资子公司安迪科的通知，其收到江苏省药监局下发的《放射性药品生产许可证》，新增安徽合肥核药生产中心，标志着安迪科的安徽合肥核药生产中心已达到投产要求，安迪科将新增一个核药生产中心。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300035733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2443118509","title":"东诚药业(002675.SZ)：合肥核药生产中心投入运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2443118509","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443118509?lang=zh_cn&edition=full","pubTime":"2024-06-13 19:05","pubTimestamp":1718276706,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)公告，公司收到全资子公司南京江原安迪科正电子研究发展有限公司(简称“安迪科”)的通知，通知其收到江苏省药品监督管理局下发的《放射性药品生产许可证》，新增安徽合肥核药生产中心。此次审查的通过标志着安迪科的安徽合肥核药生产中心已达到投产要求，安迪科将新增一个核药生产中心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2440423854","title":"东诚药业（002675）6月3日主力资金净卖出2098.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440423854","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440423854?lang=zh_cn&edition=full","pubTime":"2024-06-04 09:20","pubTimestamp":1717464042,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月3日收盘，东诚药业报收于13.8元，下跌5.8%，换手率3.46%，成交量26.49万手，成交额3.74亿元。近5日资金流向一览见下表：东诚药业融资融券信息显示，融资方面，当日融资买入3371.24万元，融资偿还3650.33万元，融资净偿还279.09万元。东诚药业主营业务：肝素钠原料药、硫酸软骨素的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060400012771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2440459431","title":"6月3日东诚药业跌5.80%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2440459431","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440459431?lang=zh_cn&edition=full","pubTime":"2024-06-03 16:25","pubTimestamp":1717403119,"startTime":"0","endTime":"0","summary":"证券之星消息，6月3日东诚药业跌5.80%，收盘报13.8元，换手率3.46%，成交量26.49万手，成交额3.74亿元。重仓东诚药业的公募基金请见下表：该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为16.8。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为银河医药混合A。银河医药混合A目前规模为5.02亿元，最新净值0.5042，较上一交易日上涨0.84%，近一年下跌20.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300018005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1515","159938","09939","BK1574","002675"],"gpt_icon":0},{"id":"2439769465","title":"5月30日东诚药业涨5.40%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2439769465","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439769465?lang=zh_cn&edition=full","pubTime":"2024-05-30 16:21","pubTimestamp":1717057297,"startTime":"0","endTime":"0","summary":"证券之星消息，5月30日东诚药业涨5.40%，收盘报14.25元，换手率3.11%，成交量23.81万手，成交额3.38亿元。重仓东诚药业的公募基金请见下表：该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为16.8。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为银河医药混合A。银河医药混合A目前规模为5.02亿元，最新净值0.501，较上一交易日上涨0.48%，近一年下跌22.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053000028686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","002675","09939","BK0239","BK1574","BK1161"],"gpt_icon":0},{"id":"2439658017","title":"独家药品概念盘中拉升，东诚药业涨4.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439658017","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439658017?lang=zh_cn&edition=full","pubTime":"2024-05-30 09:54","pubTimestamp":1717034046,"startTime":"0","endTime":"0","summary":"05月30日，独家药品概念盘中拉升，截至09点54分，独家药品概念整体指数上涨0.51%，报861.870点。从个股上来看，该概念的成分股中，东诚药业涨4.66%，甘李药业、新里程、特宝生物涨幅居前。从资金上来看，截止发稿，独家药品概念概念主力净流入为-285.51万，其中甘李药业受到资金热捧，主力净流入2362.13万；拉长时间线来看，该板块近20日主力资金净流入-29.47亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240530095406aef2718c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240530095406aef2718c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","002675","603087"],"gpt_icon":0},{"id":"2438367594","title":"东诚药业（002675）5月27日主力资金净买入497.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2438367594","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438367594?lang=zh_cn&edition=full","pubTime":"2024-05-28 09:13","pubTimestamp":1716858813,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月27日收盘，东诚药业报收于13.57元，上涨4.95%，换手率2.29%，成交量17.52万手，成交额2.36亿元。近5日资金流向一览见下表：东诚药业融资融券信息显示，融资方面，当日融资买入1398.37万元，融资偿还1866.81万元，融资净偿还468.43万元。东诚药业主营业务：肝素钠原料药、硫酸软骨素的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052800011760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2437707408","title":"东诚药业最新公告：控股子公司获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2437707408","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437707408?lang=zh_cn&edition=full","pubTime":"2024-05-24 16:38","pubTimestamp":1716539908,"startTime":"0","endTime":"0","summary":"东诚药业公告，控股子公司烟台蓝纳成生物技术有限公司收到国家药监局核准签发的177Lu-LNC1010注射液药物临床试验批准通知书，将于近期开展临床试验。该药物是一种靶向生长抑素受体2的放射性体内治疗药物，适用于治疗生长抑素受体2阳性的胃肠胰神经内分泌瘤。目前全球仅有诺华公司的同靶点药物Lutathera上市，2023年销售额为6.05亿美元。药品从研制到上市周期长，存在不确定性，公司将积极推进研发项目并及时披露进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052400030867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK1141","BK0239","BK1576","002675","BK1583"],"gpt_icon":0},{"id":"2437702734","title":"东诚药业(002675.SZ)：¹⁷⁷Lu-LNC1010注射液临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2437702734","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437702734?lang=zh_cn&edition=full","pubTime":"2024-05-24 16:26","pubTimestamp":1716539199,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)发布公告，公司控股子公司烟台蓝纳成生物技术有限公司(简称“蓝纳成”)收到中国国家药品监督管理局核准签发的关于¹⁷⁷Lu-LNC1010注射液的药物临床试验批准通知书，将于近期开展临床试验。据悉，公司在研产品¹⁷⁷Lu-LNC1010注射液是一种靶向生长抑素受体2的放射性体内治疗药物，适用于治疗生长抑素受体2(SSTR2)阳性的胃肠胰神经内分泌瘤(GEP-NETs)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1125713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675","BK0239","BK1141","BK1583","03347","BK1576"],"gpt_icon":0},{"id":"2437257291","title":"东诚药业：钇90项目正在按照预期计划进行临床前相关项目的整理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2437257291","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437257291?lang=zh_cn&edition=full","pubTime":"2024-05-22 18:03","pubTimestamp":1716372229,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业05月22日在投资者关系平台上答复投资者关心的问题。那期的报告可以了解钇90的研发进度，感谢！东诚药业董秘：您好，钇90项目正在按照预期计划进行临床前相关项目的整理工作，感谢您的关注！投资者：尊敬的公司管理层，东诚药业公布的2024年1季报显示核药收入较之2023年同期下降2.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052200033052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2012-05-25","address":"山东省烟台市福山区经济技术开发区长白山路7号","stockEarnings":[{"period":"1week","weight":-0.0299},{"period":"1month","weight":-0.0521},{"period":"3month","weight":-0.0881},{"period":"6month","weight":-0.2123},{"period":"1year","weight":-0.2062},{"period":"ytd","weight":-0.3378}],"companyName":"烟台东诚药业集团股份有限公司","boardCode":"AI0027","perCapita":"32360股","boardName":"医药制造业","registeredCapital":"82459万元","compareEarnings":[{"period":"1week","weight":-0.0307},{"period":"1month","weight":-0.0275},{"period":"3month","weight":-0.064},{"period":"6month","weight":-0.0066},{"period":"1year","weight":-0.1013},{"period":"ytd","weight":-0.0282}],"survey":"　　烟台东诚药业集团股份有限公司的主营业务为生化原料药、中西药制剂、放射性核素药物的研发、生产、销售。主要产品为原料药相关产品、制剂产品、核药产品。公司是国内最大的生化原料药供应商之一。公司肝素类药物关键制备技术及质控体系创新与应用，获得中国商业联合会科学技术奖一等奖。","serverTime":1722147891605,"listedPrice":26,"stockholders":"23663人(较上一季度增加17.36%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东诚药业,002675,东诚药业股票,东诚药业股票老虎,东诚药业股票老虎国际,东诚药业行情,东诚药业股票行情,东诚药业股价,东诚药业股市,东诚药业股票价格,东诚药业股票交易,东诚药业股票购买,东诚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}